Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study [0.03%]
乳腺癌患者辅助内分泌治疗的不良反应和服药依从性变化：来自VICAN2研究的结果
Eqbal Radwan,Victoria Memoli,Lorène Seguin et al.
Eqbal Radwan et al.
Purpose: Adjuvant endocrine therapy (AET) lowers breast cancer recurrence risk and improves overall survival. However, some women have suboptimal adherence, mainly due to difficulties coping with side effects. We identifi...
Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor [0.03%]
细胞周期蛋白依赖性激酶4/6抑制剂治疗后HR+/HER2-晚期乳腺癌患者接受长春瑞滨与吉西他滨联合治疗的抗肿瘤活性研究
Pablo Jara,Marc Ariant,Roberto Jiménez et al.
Pablo Jara et al.
Objectives: To evaluate the clinical benefit of the vinorelbine-gemcitabine every two weeks (VNR-GEMQ2W) regimen in patients with hormone receptor-positive (HR +)/HER2- advanced breast cancer (ABC) treated at a tertiary c...
Factors associated with receipt of surveillance breast MRI among racially and ethnically diverse women with operable breast cancer [0.03%]
接受乳房磁共振成像监测的因素——具有可操作性乳腺癌的种族和族裔多样化的女性
Preeti Kakani,Vicky Ro,Julia E McGuinness et al.
Preeti Kakani et al.
Purpose: Due to increased sensitivity for early detection compared to mammography, breast MRI is increasingly used for surveillance screening in women with breast cancer, especially in those diagnosed at a young age or wi...
Impact of public vs. private insurance coverage on quality of life of women with early-stage estrogen receptor-positive breast cancer [0.03%]
公共保险和私人保险对雌激素受体阳性早期乳腺癌患者生活质量的影响
Danielle Laperche-Santos,Daniele Assad-Suzuki,Heloisa Resende et al.
Danielle Laperche-Santos et al.
Background: Quality of life (QOL) data for the Brazilian population with breast cancer are scarce. This study aimed to evaluate QOL in Brazilian women with early-stage breast cancer treated with adjuvant endocrine therapy...
Comment on "Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis" [0.03%]
关于“基线血红蛋白和中性粒细胞与淋巴细胞比率作为转移性三阴性乳腺癌患者二线及以后使用sacituzumab govitecan治疗的预后生物标志物：一项真实世界分析”的评论
S Dhanya Dedeepya,Vaishali Goel,Nivedita Nikhil Desai
S Dhanya Dedeepya
This commentary appraises Pieniążek et al.'s study on hematologic prognostic markers in sacituzumab govitecan-treated mTNBC, emphasizing residual confounding, absent Trop-2 data, limited modeling flexibility, and incomplete handling of mi...
Patient perspectives on artificial intelligence in mammography interpretation: a comparative survey study of safety-net and academic hospital settings [0.03%]
受试者视角下的乳腺摄影人工智能解读研究：安全网与学术医院的比较调查研究
Jenifer Chisom Ogu,B Bersu Ozcan,Basak E Dogan et al.
Jenifer Chisom Ogu et al.
Purpose: To evaluate and compare patient perceptions of artificial intelligence (AI) use in mammogram interpretation across academic and safety-net healthcare settings. ...
Comparative Study
Breast cancer research and treatment. 2025 Dec 3;215(1):25. DOI:10.1007/s10549-025-07870-9 2025
Using the cancer aging and research group- breast cancer (CARG-BC) predictive model in older adults (OA) with early breast cancer: an external validation study [0.03%]
一项在老年期早期乳腺癌患者中使用癌症老化研究组-乳腺癌（CARG-BC）预测模型的外部验证研究
Neha Pathak,Ashley Kimmel,Yael Berner-Wygoda et al.
Neha Pathak et al.
Purpose: Decision-making for chemotherapy in early breast cancer (EBC) in OA (older adults: age ≥ 65 years) is complex due to frailty, multimorbidity, and competing risks for mortality. Magnuson (2021) developed a chemot...
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer [0.03%]
评估HER2阳性转移性乳腺癌接受T-DXd治疗后的治疗策略
Sophia Zelizer,Grace B Gallagher,Mithat Gonen et al.
Sophia Zelizer et al.
Purpose: Trastuzumab deruxtecan (T-DXd) is an antibody drug conjugate (ADC) approved for the treatment of HER2-positive metastatic breast cancer (MBC). Despite its efficacy, eventual resistance and disease progression are...
Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast [0.03%]
乳腺经典型和多形性侵袭性小叶癌患者的伴发小叶原位癌对复发结局的影响
Mandeep Kaur,Astrid Quirarte,Anna Vertido et al.
Mandeep Kaur et al.
Purpose: We investigated outcomes of invasive lobular carcinoma (ILC) with or without concurrent lobular carcinoma in situ (LCIS) in patients with classic or pleomorphic ILC. ...
High PARP1 expression is associated with proliferative tumor biology in breast cancer [0.03%]
PARP1高表达与乳腺癌增殖性肿瘤生物学相关
Farhad Ghasemi,Jun Arima,Kazuaki Takabe
Farhad Ghasemi
Background: Poly [ADP-ribose] polymerase (PARP) 1 enzyme is vital in DNA repair mechanisms. PARP1 inhibitors are in clinical use due to synthetic lethality in homologous-recombination repair-deficient tumors with germline...